News

Pharmos said that it does not expect a material charge against operations to result from this undertaking. The Israeli subsidiary will continue efforts to expand and exploit the

This request for approval will be accompanied by a proxy proposal, also approved by the board, to sell the company’s genomics assets to Ocimum Biosolutions. Ownership of the

The offer price represents an approximate 32% premium over the 10-day average closing price per share for E-Z-EM as of October 29, 2007, the last trading day prior

The Phase I study is designed to evaluate the safety, tolerability, and pharmacokinetics of the HIF-1 alpha antagonist in a daily for five days schedule. Hypoxia-inducible factor-1 alpha

The marketing authorization application is based on data from three Phase III studies of rivaroxaban in the prevention of venous thromboembolism after major orthopedic surgery of the lower

The multi-center, prospective randomized Phase III clinical trial is expected to enroll approximately 100 evaluable children with hepatoblastoma, an orphan disease, being treated with cisplatin. Patients will be

Javelin views the UK Dyloject approval as an attractive opportunity to inaugurate its European Dyloject franchise. Javelin’s UK marketing authorization is the first step in securing distribution and

According to the license agreement, Foamix has the exclusive rights to use the dual-chamber device for all topical and intra-vaginal drug products requiring prescription. The device is protected

Bio-Trials provides clinical monitoring, clinical site coordination, regulatory support, study management and supply distribution services. Jeff Thomis, president of global clinical development services for Quintiles, said: “The acquisition